RxDoctor Payments Data

Shawn O'Haver

Primary Care · Lake Havasu City, AZNPI 1922450493

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 53.3% of the total. Reporting peaked in 2021 at $987 and has fallen 87.0% since, to $128 in 2024.

$1,817in general payments, 2019–2025

Across 36 payments — averaging $50.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$969
  • Boston Scientific$701
  • Biohaven Pharmaceutical Holding Company Ltd.$45
  • Lilly USA, LLC$32
  • Amgen$32
  • Abbott$25
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$80044%
  • Food & beverage$1,01756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,817 in reported general payments places this provider in the 80th percentile of 151 primary care providers in Arizona.

See all primary care providers in Arizona

Medicare billing

Part B allowed, 2024
$132,423
Medicare patients
252
Services billed
2,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$173,541
EliquisApixaban40$49,599
RybelsusSemaglutide16$31,294
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$28,388
MyrbetriqMirabegron13$18,094
Breo ElliptaFluticasone/Vilanterol16$8,149
Testosterone Cypionate39$2,590
Tamsulosin Hcl171$2,418
Omeprazole184$2,218
Duloxetine Hcl100$2,138
Celecoxib91$2,109
Propranolol Hcl ErPropranolol Hcl50$1,666
Levothyroxine Sodium150$1,348
Trazodone Hcl102$1,332
Trimethoprim12$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$13$204,836128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 151 primary care providers in Arizona.

Other primary care in Lake Havasu City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →